Optifar SRL
3.2 FTEThe score of Optifar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2024
Change 2021 → 2024: Equity +56 % Total assets +44 % Headcount (avg FTE) +28 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Optifar's annual accounts
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Net result | 113,520 € | ||||
| Equity | 962,948 € | ||||
| Cash | 17,757 € | ||||
| EBITDA | 174,272 € | ||||
| Total assets | €1.54m |
Filed annual accounts
- Year ended 31 Dec 2024filed on 28 May 2025
- Year ended 31 Dec 2023filed on 30 Sep 2024
- Year ended 31 Dec 2022filed on 10 Aug 2023
- Year ended 31 Dec 2021filed on 26 Aug 2022
- Year ended 31 Dec 2020filed on 30 Sep 2021
Optifar's financial analysis
- Solvency62.5%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Optifar
Optifar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0479.850.684
- VAT number
- BE0479850684
- Peppol
- Registered · 0208:0479850684 · as of 08 Nov 2026
- Legal form
- SRL
- Incorporated
- 26 Mar 2003
- Registered office
- 1703 Dilbeek
- Size
- Micro · 3.2 FTE
- Latest accounts
- 2024 · filed on 28 May 2025
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Optifar (SRL) has been based in Dilbeek since 2003, active in: retail sale of pharmaceutical products. For 2024, it reports a net profit of 113,520 € and equity of 962,948 €; its revenue is not published. With 3.2 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 62.5%, above the median of its sector (44.2%).
Companies similar to Optifar
Companies in the same business, of comparable size and area, outside its group.
- Covarmed Farma Manufacture of medical and dental instruments and supplies Kortrijk · balance sheet €1.69m
- Sobegapharma Manufacture of basic pharmaceutical products Mons · balance sheet €1.04m
- Optiek & Hoorcentrum Joost Manufacture of medical and dental instruments and supplies Lierde · balance sheet 837,528 €
- Pharmacie Roland Retail sale of pharmaceutical products Villers-le-Bouillet · balance sheet €1.21m
- Apotheek Coene Retail sale of pharmaceutical products Zonnebeke · balance sheet €1.17m
- Apotheken Peeters Retail sale of pharmaceutical products Lummen · balance sheet €1.44m
- Optifarm Retail sale of pharmaceutical products Zottegem · balance sheet €2.46m
- 't Brillenhuys Retail sale of medical and orthopaedic goods Leopoldsburg · balance sheet €1.47m
Frequently asked questions about Optifar
What is the revenue of Optifar?
Optifar files its accounts in a format where revenue is optional: it is not published for 2024.
What is the VAT number of Optifar?
In Belgium, the VAT number is the company number prefixed with BE: BE0479850684 for Optifar, if the company is VAT-registered. Its company number (CBE) is 0479.850.684.
Where is the registered office of Optifar?
According to the CBE register, the registered office of Optifar is in 1703 Dilbeek.
What is the equity of Optifar?
At the close of the 2024 financial year, the equity of Optifar amounts to 962,948 €, a solvency of 62.5% of total assets.
How many people work at Optifar?
3.2 full-time equivalents on average according to the 2024 social balance sheet.
Who manages Optifar?
The register lists 2 active mandates at Optifar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Optifar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →